Biosynthetic Human Insulin and Insulin Analogs

Abstract

Background: Biosynthetic human insulins and analogs have replaced animal insulins and permitted structural modifications to alter the rate of absorption, duration of action, improve reproducibility of effects, and modulate relative efficacy in various target tissues. Several forms of rapidly acting insulins nearly achieve rapid pharmacokinetics and pharmacodynamics similar to first-phase insulin release. There is need for even faster-acting analogs to mimic normal physiology and improve control of postprandial glycemic excursions. Two biosynthetic insulin analogs have sufficiently long duration of action for use as once-daily basal insulins; controversy persists regarding their respective risks of hypoglycemia and relative glycemic variability. Results: Basal-bolus therapy and insulin pump therapy, including closed-loop automated insulin delivery, require rapid-acting insulin analogs. The longer acting insulins can provide stable, reproducible basal insulin with reduced rates of hypoglycemia, particularly nocturnal hypoglycemia, greater efficacy in reducing mean glucose and glucose variability while increasing time in glucose target range. Inhalable human insulin provides very rapid action. Premixture of rapid-acting analogs with protamine has been useful for some patients with type 2 diabetes. An insulin analog with preferential efficacy at the liver has been developed and tested clinically but not marketed. Current research is aimed at developing even faster-acting insulin analogs. Long-acting basal insulins coformulated with GLP-1 receptor agonists or with a rapidly acting insulin analog have valuable clinical applications. Excipients, chaperones, local heating of the infusion site, and hyaluronidase have also been used to accelerate the absorption of insulin analogs. Conclusions: Biosynthetic human insulins have radically revolutionized management of both type 1 and type 2 diabetes worldwide. The ability to manipulate the structure and formulation of insulin provides for more physiologic pharmacokinetics and pharmacodynamics, enabling improved glycemic control, reduced risk of hypoglycemia, and reduced rates of long-term complications.

Novel glucose-responsive nanoparticles based on p-hydroxyphenethyl anisate and 3-acrylamidophenylboronic acid reduce blood glucose and ameliorate diabetic nephropathy

“…For the insulin delivery system, it is imperative to maintain the bioactive functionality of insulin, and the conformation of insulin is closely related to its biological activity [ 48 ]. We next used CD to evaluate the conformational comparison of insulin released by nanoparticles and standard insulin.…”

Beneficial Xultophy Treatment from Medical and Social Points of View

“…As a result, diabetes control became unstable and HbA1c levels fluctuated from 6.2-8.4% (Figure 1). Novolin 30R twice daily could not give enough glucose control (20). Regarding this treatment way, he was formerly provided in a university hospital.…”

The Other Face of Insulin—Overdose and Its Effects

“…Insulin is the most effective drug in lowering glycemia, and for patients with type 1 diabetes (T2D), it is a life-saving treatment [ 7 ]. Therefore, it is important to understand its effects, clinical relevance, and the potential risks associated with taking it.…”

“…In T1D, basal-bolus is virtually always the treatment of choice, preferably in an intensive insulin therapy model with bolus dose adjustment according to the specific meal, current blood glucose and planned physical activity. In the treatment of type 2 diabetes (T2D), if insulin therapy is required, a single injection of basal insulin is usually used initially, but full insulin therapy is often ultimately required [ 7 ]. For elderly people, who cannot cope with the method of multiple injections, it is possible to use mixed preparations.…”